Therefore, testing AYA patients for MMRD (with immunostains, or sequencing) in newly diagnosed high grade IDH-mutant gliomas, or recurrent gliomas previously treated with alkylating chemotherapy is clinically valuable. This evidence concerns the gene IDH1 and glioma.